BNT162

Pfizer Provides Full-Year 2024 Guidance

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, Health, Finance, Banking, Pharmaceutical, Biotechnology, Research, Safety, Acquisition, Pediatrics, Overview, Federation, Annual report, Risk, COVID-19 vaccine, Clinical trial, Intellectual property, EPS, Formula, Vaccine, Messenger, COVID-19, Pfizer–BioNTech COVID-19 vaccine, Omicron, Global Economic Symposium, GAAP, Analysis, BioNTech, MD, EST, Public, BNT162, Dive (Belgian band), Financial condition report, Publication, Result, Originality, Security (finance), Pharmaceutical industry, Risk management, Pfizer, Seagen

Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.

Key Points: 
  • Financial guidance for Adjusted(5) diluted EPS is calculated using approximately 5.75 billion weighted average shares outstanding, and assumes no share repurchases in 2023 or 2024.
  • As announced on December 12, 2023, Pfizer and Seagen have received all required regulatory approvals for the closing of the acquisition.
  • Pfizer expects to complete the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Financial guidance for full-year 2024 reflects the following:
    Guidance for Adjusted(5) diluted EPS assumes diluted weighted-average shares outstanding of approximately 5.75 billion shares, and assumes no share repurchases in 2024.

Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, COVID-19, Pediatrics, Public, Vaccine, Government, Risk, Intellectual property, CDC, Safety, US Foods, VAERS, FDA, Vaccination, COVID-19 vaccine, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Clinical trial, Publication, Federation, BNT162, Korea Disease Control and Prevention Agency, Research, Pharmaceutical industry, Pfizer

Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.

Key Points: 
  • Call the vaccination provider or healthcare provider about bothersome side effects or side effects that do not go away.
  • Please include “Pfizer-BioNTech COVID-19 Vaccine(2023-2024 Formula) EUA” in the first line of box #18 of the report form.
  • In addition, individuals can report side effects to Pfizer Inc. at www.pfizersafetyreporting.com or by calling 1-800-438-1985.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for Single-Dose mRNA-Based Vaccine Candidate Against COVID-19 and Influenza

Retrieved on: 
Friday, December 9, 2022
Pediatrics, Immunotherapy, BioNTech, Clinical trial, Marketing, Omicron, Emergency Use Authorization, Safety, Originality, Science, Cancer, Peer review, Regeneron Pharmaceuticals, Pierre Geneves, News, Vaccine, RNA transfection, Hoffmann-La Roche, Infection, Research, Risk, Form 6-K, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Publication, Medical device, Genentech, Pfizer, BNT162

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Retrieved on: 
Thursday, December 8, 2022
Pediatrics, Immunotherapy, BioNTech, Clinical trial, FDA, Marketing, Omicron, Safety, Originality, Science, Cancer, Peer review, Regeneron Pharmaceuticals, DO, Pierre Geneves, News, Vaccine, Vaccination, EUA, RNA transfection, Hoffmann-La Roche, Infection, BNT162, Research, Risk, Pfizer–BioNTech COVID-19 vaccine, COVID-19, Publication, Form, Pharmaceutical industry, Medical device, EU, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Retrieved on: 
Thursday, December 8, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, COVID-19, Clinical Trials, Pfizer–BioNTech COVID-19 vaccine, Publication, Vaccination, State, BioNTech, JD, Immunotherapy, Human services, Omicron, Infection, Science, Cancer, American Animal Hospital Association, Research, United States Department of Health and Human Services, Pediatrics, FDA, Vaccine, Peer review, Regeneron Pharmaceuticals, Form, News, Health, COVID-19, Pierre Geneves, Clinical trial, RNA transfection, Safety, Originality, Hospital, EUA, American Academy of Pediatrics, Hoffmann-La Roche, BNT162, Marketing, U.S. Department of Defense Strategy for Operating in Cyberspace, Risk, Pharmaceutical industry, Medical device, Pfizer, Genentech, EU

For more than 170 years, we have worked to make a difference for all who rely on us.

Key Points: 
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • We routinely post information that may be important to investors on our website at www.pfizer.com .
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Monday, November 28, 2022
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, COVID-19, Growth, EST, Science, Inc., PFE, Conference, Pfizer–BioNTech COVID-19 vaccine, BNT162, Evercore, Webcast, NYSE, News, Clinical trial, Vaccine, Safety, Pharmaceutical industry, Pfizer

To view and listen to the webcast, visit our web site at www.pfizer.com/investors .

Key Points: 
  • To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Retrieved on: 
Friday, November 18, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, BNT162, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, Ageing, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, Medical device, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • In addition, to learn more, please visit us on and follow us on Twitter at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer .
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection

Retrieved on: 
Wednesday, November 16, 2022
Marketing, COVID-19, BioNTech, Science, Hoffmann-La Roche, Risk, Regeneron Pharmaceuticals, Omicron, Pediatrics, Pierre Geneves, RNA transfection, Infection, Cancer, Pfizer–BioNTech COVID-19 vaccine, Research, Form, Originality, News, Publication, Clinical trial, Peer review, Immunotherapy, Vaccine, Safety, BNT162, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Retrieved on: 
Friday, November 11, 2022
Other Professional Services, Biotechnology, Pharmaceutical, Finance, General Health, Health, Professional Services, Other Health, Webcast, Clinical trial, EST, BNT162, PFE, U.S. Securities and Exchange Commission, Pfizer–BioNTech COVID-19 vaccine, Vaccine, Safety, Inc., Conference, Science, COVID-19, Growth, NYSE, YouTube, News, Pharmaceutical industry, Pfizer

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November 18, 2022 at 8:45 a.m. EST.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe Research Healthcare Conference on Friday, November 18, 2022 at 8:45 a.m. EST.
  • To view and listen to the webcast, visit our web site at www.pfizer.com/investors .
  • At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
  • Pfizer assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Retrieved on: 
Friday, November 4, 2022
BNT162, Company, Private Securities Litigation Reform Act, Science, Research, Awareness, Peer review, Ageing, RNA transfection, EMA, Cancer, Publication, Safety, BioNTech, Pediatrics, COVID-19, Marketing, YouTube, Omicron, Pierre Geneves, U.S. Securities and Exchange Commission, Originality, Regeneron Pharmaceuticals, Clinical trial, Vaccine, Risk, Infection, Hoffmann-La Roche, Form, Pfizer–BioNTech COVID-19 vaccine, SEC, Immunotherapy, News, Program, Genentech, Pfizer

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

Key Points: 
  • Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
  • For more than 170 years, we have worked to make a difference for all who rely on us.
  • Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
  • This press release contains forward-looking statements of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995.